Although statistically insignificant, results of a randomized study determined the potential for nurse-led interventions as adjunct posttreatment care for lymphoma survivors.
Chimeric antigen receptor T-cell therapy boosts a patient’s own immune cells.
Increased incidences found for lymphoma, lung cancer (in male patients), and cervical cancer.
Autologous stem cell transplantation explored for high-risk, early therapy failure FL prior to rituximab use
FDA requested recall to protect women from breast implant-associated anaplastic large cell lymphoma.
View treatment regimens for Waldenstrom’s Macroglobulinemia/Lymphoplasmacytic Lymphoma, including combination therapies with bortezomib and more.
Researchers evaluated whether time to diagnosis of diffuse large B-cell lymphoma was associated with prognosis and survival.
Allergan is recalling BIOCELL textured breast implants and tissue expanders due to the potential risk for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The move to recall was based on an analysis of medical device reports submitted to the Food and Drug Administration (FDA) related to BIA-ALCL and BIA-ALCL-related deaths associated with these devices. “Once…
This US FDA has approved Ruxience for the treatment of adult patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
A retrospective study sought to determine the risk of solid-tumor second malignancy associated with an infectious etiology for patients with certain lymphomas or leukemias.
